This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Histogenics Stock (NASDAQ:HSGX) Get Histogenics alerts:Sign Up Key Stats Today's Range$1.84▼$1.9250-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume4.66 million shsAverage Volume9.06 million shsMarket Capitalization$175.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts. Read More Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HSGX Stock News HeadlinesTraphaco JSC TRAJuly 31, 2024 | morningstar.comMFeargal Sharkey: Desperate revival of failed policies doesn’t add upApril 7, 2023 | thetimes.co.ukTA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 16 at 1:00 AM | Porter & Company (Ad)Aspect Biosystems Appoints Three New Board Members - StreetInsider.comSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - Business WireSeptember 21, 2022 | businesswire.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 24, 2022 | investing.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseAugust 5, 2022 | stockhouse.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comJune 23, 2022 | gurufocus.comSee More Headlines HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.10. When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an initial public offering on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Histogenics investors own include Verastem (VSTM), Novavax (NVAX), SCYNEXIS (SCYX), Ocular Therapeutix (OCUL) and OPKO Health (OPK). Company Calendar Last Earnings8/09/2018Today7/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-186.00Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$175.95 million OptionableNot Optionable Beta3.10 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:HSGX) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe Lithium Gold Rush Minted A New $1B UnicornThe Lithium Gold Rush Minted A New $1B Unicorn This lithium producer surpassed a $1B private valuation, joi...EnergyX | SponsoredWhat Saudi Arabia just did to the dollar changes everythingIn June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...Golden Portfolio | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings (NASDAQ: VWAV) is developing a full-stack defense technology platform integrating AI, RF s...Equiscreen | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogenics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
